Velan Capital Investment Management LP Takes $822,000 Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Velan Capital Investment Management LP purchased a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 28,685 shares of the specialty pharmaceutical company's stock, valued at approximately $822,000. Collegium Pharmaceutical makes up 0.7% of Velan Capital Investment Management LP's investment portfolio, making the stock its 17th largest holding. Velan Capital Investment Management LP owned about 0.09% of Collegium Pharmaceutical as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of COLL. New Age Alpha Advisors LLC purchased a new stake in Collegium Pharmaceutical during the 4th quarter worth approximately $40,000. KBC Group NV increased its stake in Collegium Pharmaceutical by 72.5% during the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after buying an additional 982 shares in the last quarter. Virtus Fund Advisers LLC increased its stake in Collegium Pharmaceutical by 30.5% during the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company's stock worth $69,000 after buying an additional 565 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock worth $71,000 after buying an additional 316 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in Collegium Pharmaceutical by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after buying an additional 642 shares in the last quarter.

Collegium Pharmaceutical Trading Up 0.1%

Collegium Pharmaceutical stock traded up $0.04 during midday trading on Friday, hitting $28.86. 178,265 shares of the stock were exchanged, compared to its average volume of 427,547. Collegium Pharmaceutical, Inc. has a fifty-two week low of $23.23 and a fifty-two week high of $42.29. The stock has a market capitalization of $927.33 million, a price-to-earnings ratio of 12.44 and a beta of 0.63. The stock's 50-day simple moving average is $28.11 and its 200 day simple moving average is $29.74. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $177.76 million for the quarter, compared to analyst estimates of $174.96 million. During the same quarter in the previous year, the business posted $1.45 earnings per share. Collegium Pharmaceutical's revenue for the quarter was up 22.7% on a year-over-year basis. On average, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have commented on COLL shares. Wall Street Zen lowered Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. Needham & Company LLC reiterated a "buy" rating and set a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Piper Sandler reiterated a "neutral" rating and set a $37.00 price objective (up from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. Finally, HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.80.

Insider Buying and Selling

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 1,949 shares of the stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $30.00, for a total transaction of $58,470.00. Following the completion of the transaction, the chief financial officer now owns 177,195 shares of the company's stock, valued at $5,315,850. This trade represents a 1.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the transaction, the executive vice president now directly owns 154,204 shares of the company's stock, valued at approximately $4,330,048.32. This trade represents a 20.60% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 81,693 shares of company stock worth $2,334,994. Insiders own 2.51% of the company's stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.